Novo Nordisk Launches Wegovy in South Africa, Ramping Up Obesity Drug Battle with Eli Lilly
Johannesberg: Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa and stepping up competition with Eli Lilly's Mounjaro launched in the country eight months earlier.
South Africa, which has the continent's fourth-highest number of adults with diabetes, according to the International Diabetes Federation, would represents a key growth opportunity for obesity treatments.
"One in two adults right now in South Africa is living with excess weight or obesity," Sara Norcross, general manager of Novo Nordisk South Africa, said at the launch event.
"We know that over two-thirds of women and about one in three men are currently living with obesity."
Norcross said that Wegovy, which will be available from Friday, was licensed and registered for weight-loss management in South Africa. Novo already sells Ozempic in South Africa for diabetes treatment.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.